Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695642 | 1.00 | HDAC1 (0.55) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL30724412 | 0.94 | HDAC1 (0.49) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL9823156 | 0.93 | HDAC1 (0.54) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL6539902 | 0.93 | HDAC1 (0.49) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL1798901 | 0.90 | HDAC1 (0.52) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL6540918 | 0.88 | HDAC1 (0.51) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL13617803 | 0.88 | HDAC1 (0.52) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL13708399 | 0.88 | HDAC1 (0.52) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL27540555 | 0.88 | HDAC1 (0.51) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL2595460 | 0.88 | HDAC1 (0.51) | HDAC1HDAC3HDAC2NCOR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| EP-1735268-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | disclosed |
| WO-2005092836-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | HDAC1 688/4885HDAC3 356/4885HDAC2 1610/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | HDAC1 448/4885HDAC3 239/4885HDAC2 961/4885 |
| US-20110105571-A1 | Opioid Receptor Antagonists | OPRD1, OPRM1, OPRK1 | HDAC1 688/4885HDAC3 356/4885HDAC2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.